Patent SG-11201804540W-A (SG)
Title: Resorbable crosslinked form stable membrane
Inventor: STIEFEL NIKLAUS
IPC: A61K6/884
Filed: 2016-12-02
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' International Bureau res.. 00) (43) International Publication Date ..... ..sr ,„„*.) 8 June 2017 (08.06.2017) W I P0 1 PCT Organization 111111111111311111111111111111111111111111111111111111111111111111111111111111111111111111 (10) WO International 2017/093502 Publication Al Number (51) International Patent Classification: DO, DZ, EC, EE, EG, A61L 27/38 (2006.01) A61L 27/58 (2006.01) HN, HR, HU, ID, IL, A61L 27/46 (2006.01) KW, KZ, LA, LC, LK, MG, MK, MN, MW, (21) International Application Number: OM PA, PE, PG, PH, PCT/EP2016/079622 SC, SD, SE, SG, SK, (22) International Filing Date: TN, TR, TT, TZ, UA, 2 December 2016 (02.12.2016) ZW. (25) Filing Language: English (8 4 ) Designated States (unless kind of regional protection (26) Publication Language: English GM, KE, LR, LS, MW, (30) Priority Data: TZ, UG, ZM, ZW), Eurasian (AM, 15198070.3 4 December 2015 (04.12.2015) EP TJ, TM), European (AL, DK, EE, ES, FI, FR, (71) Applicant: GEISTLICH PHARMA AG [CH/CH]; LV, MC, MK, MT, NL, Bahnhofstrasse 40, 6110 Wolhusen (CH). SM, TR), OAPI (BF, ES, FI, GB, GD, GE, GH, GM, GT, IN, IR, IS, LR, LS, MX, MY, PL, PT, SL, SM, UG, MZ, AT, GB, GR, NO, BJ, CF, otherwise available): JP, KE, KG, KN, KP, KR, LU, LY, MA, MD, ME, MZ, NA, NG, NI, NO, NZ, QA, RO, RS, RU, RW SA, ST, SV, SY, TH, TJ, TM, US, UZ, VC, VN, ZA, ZM, indicated, for every ARIPO (BW, GH, NA, RW, SD, SL, ST, SZ, AZ, BY, KG, KZ, RU, BE, BG, CH, CY, CZ, DE, HR, HU, IE, IS, IT, LT, LU, PL, PT, RO, RS, SE, SI, SK, CG, CI, CM, GA, GN, GQ, (72) Inventors: STIEFEL, Niklaus; Waldstatterstrasse 31, GW, KM, ML, MR, NE, 6003 Luzern (CH). STENZEL, Sergej; Dobeligut 8, 4665 Declarations under Rule 4.17: Oftringen (CH). KAUFMANN, Raphael; Neuheim 8, — as to the identity of the 6275 Ballwil (CH). — as to applicant's entitlement TG). SN, TD, inventor to (Rule 4.17(0) apply for and be granted a (74) Agent: SAVATIER, Yves; Bahnhofstrasse 40, 6110 patent (Rule 4.170) Wolhusen (CH). Published: (81) Designated States (unless otherwise indicated, for every kind AE, AG, AL, AM, — with international search report (Art 21(3)) of national protection available): AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (54) Title: RESORBABLE CROSSLINKED FORM STABLE MEMBRANE 1 Fig r Il .4t (57) : The invention relates to: -A resorbable crosslinked form stable membrane which comprises a composite layer of col - ei c ::: : , lagen material and inorganic ceramic particles containing 1.5 to 3.5 weight parts of inorganic ceramic for 1 weight part of collagen If) material, sandwiched between two layers of elastic pretensed collagen material, the collagen material comprising 50-100 % (w/w) M collagen and 0-50 % (w/w) elastin, -the above crosslinked resorbable crosslinked form stable membrane for use as an implant to sup - CT\ o port bone formation, bone regeneration, bone repair and/or bone replacement at a non-containing dental bony defect site in a human ---... or animal, -a process for preparing the above crosslinked resorbable crosslinked foiin stable membrane comprising the steps of: (a) Preparing a composite layer of inorganic ceramic particles and collagen material, optionally crosslinking that composite layer, (b) ..::::; Assembling and glueing the composite layer of collagen material and inorganic ceramic particles between two layers of collagen ma - ei terial submitted to tensioning leading to a stretching of the collagen material in the linear region of the stress-strain curve, thereby ega ) giving a composite layer of collagen material and inorganic ceramic particles sandwiched between two layers of elastic pretensed :',.1: collagen material, and (c) Crosslinking that composite layer of collagen material and inorganic ceramic particles sandwiched between two layers of elastic pretensed collagen material, followed by a hydrophilic making treatment.